Ident. | Authors (with country if any) | Title |
---|
001167 |
Harry R. Büller [Pays-Bas] ; Alex S. Gallus [Australie] ; Gerard Pillion [France] ; Martin H. Prins [Pays-Bas] ; Gary E. Raskob [États-Unis] | Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial |
002363 |
Harvey D. White [Nouvelle-Zélande] ; Philip E. Aylward [Australie] ; Richard Gallo [Canada] ; Christoph Bode [Allemagne] ; Gabriel Steg [France] ; Steven R. Steinhubl [États-Unis] ; Gilles Montalescot [France] | Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: Insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial |
002755 |
Harvey D. White [Nouvelle-Zélande] ; Richard Gallo [Canada] ; Marc Cohen [États-Unis] ; Ph. Gabriel Steg [France] ; Philip E. Aylward [Australie] ; Christoph Bode [Allemagne] ; Steve Steinhubl [États-Unis] ; Gilles Montalescot [France] | The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment : Results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial |
002F38 |
Harvey D. White [Nouvelle-Zélande] ; Derek P. Chew [Australie] ; James W. Hoekstra [États-Unis] ; Chadwick D. Miller [États-Unis] ; Charles V. Pollack [États-Unis] ; Frederick Feit [États-Unis] ; A. Michael Lincoff [États-Unis] ; Michel Bertrand [France] ; Stuart Pocock [Nouvelle-Zélande, Royaume-Uni] ; James Ware [États-Unis] ; E. Magnus Ohman [États-Unis] ; Roxana Mehran [États-Unis] ; Gregg W. Stone [États-Unis] | Safety and Efficacy of Switching From Either Unfractionated Heparin or Enoxaparin to Bivalirudin in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Managed With an Invasive Strategy : Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial |
003165 |
Gilles Montalescot [France] ; Marc Cohen [États-Unis] ; Genevieve Salette [France] ; Walter J. Desmet [Belgique] ; Carlos Macaya [Espagne] ; Philip E. G. Aylward [Australie] ; Gabriel Steg [France] ; Harvey D. White [Nouvelle-Zélande] ; Richard Gallo [Canada] ; Steven R. Steinhubl [États-Unis] | Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention : insights from the STEEPLE trial |
004071 |
Gilles Montalescot [France] ; Harvey D. White [Nouvelle-Zélande] ; Richard Gallo [Canada] ; Marc Cohen [États-Unis] ; P. Gabriel Steg [France] ; Philip E. G. Aylward [Australie] ; Christoph Bode [Allemagne] ; Massimo Chiariello [Italie] ; Spencer B. Iii King [États-Unis] ; Robert A. Harrington [États-Unis] ; Walter J. Desmet [Belgique] ; Carlos Macaya [Espagne] ; Steven R. Steinhubl [États-Unis] | Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention |
005676 |
Geno Merli [États-Unis, France, Norvège, Israël, Australie, Suède, Pologne] ; Theodore E. Spiro ; Carl-Gustav Olsson ; Ulrich Abildgaard ; Bruce L. Davidson ; Amiram Eldor ; Darlene Elias ; Andrew Grigg ; Dominique Musset ; George M. Rodgers ; Arthur A. Trowbridge ; Roger D. Yusen ; Krystyna Zawilska | Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease |